bevacizumab,panitumumab
takeda,amgen,roche
[]
 presenting ctdna-guided subgroup analysis of paradigm; ctdna guided negative hyperselection markers
kras, nras, braf (v600e),
pten, egfr (ecd), her2 and
met amplifications, alk, ret, or ntrk1 fusions trumped sidedness in response to anti-egfr benefit #gi23 
MD Anderson Chief Fellow l Hematology/Oncology @MDAndersonNews l Via @IMResidencyDuke @CWRUSOM @UNCcollege l GI Oncology l Opinions my own.